Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model

Oncology Research

Volumn 21, Issue 4, 2014, Pages 193-200

  Zhang, Lijie ^a   Chen, Juanjuan ^a   Song, Xiao ^a   Wen, Weigang ^a   Li, Yan ^a   Zhang, Yu ^a   Yin, Yanhui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cancer testis antigen; HCA587 (MAGE C2); Synthetic long peptide (SLP); Tumor; Vaccine

Indexed keywords

CANCER TESTIS ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; PEPTIDE VACCINE; CANCER VACCINE; MAGEC2 PROTEIN, HUMAN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SYNTHESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE; TH1 CELL; VACCINATION; ANIMAL; C57BL MOUSE; CELL GROWTH; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MALE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 84921435079     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504014X13887748696789     Document Type: Article

References (29)

1. Simpson, A. J.; Caballero, O. L.; Jungblulh, A.; Chen, Y. T.: Old, L. J. Cancer/leslis antigens, gamelogenesis and cancer. Nal. Rev. Cancer 5(8):615-625; 2005.
2. Caballero, O. L.; Chen, Y. T. Cancer/testis (CT) antigens: Poienlial targets for immunotherapy. Cancer Sci. 100(11):2014-2021:2009.
3. Li, B.; Qian, X. P.; Pang, X. W.; Zou, W. Z; Wang, Y. P.; Wu, H. Y; Chen, W. F. HCA587 antigen expression in normal tissues and cancers: Correlation with tumor differentiation in hepatocellular carcinoma. Lab. Invest. 83(8):1185-1192;2003.
4. Lucas, S.; De Plaen, E.; Boon, T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 87(1):55-60; 2000.
5. Wang, Y; Han, K. J.; Pang, X. W.; Vaughan, H. A.; Qu, W.; Dong, X. Y; Peng, J. R.; Zhao, H. T.; Rui, J. A.; Leng, X. S.; Cebon, J.; Burgess, A. W.; Chen, W. F. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J. Immunol. 169(2):1102-1109;2002.
6. Xing, Q.; Pang, X. W.; Peng, J. R.; Yin, Y. H.; Li, Y; Yu, X.; Zhou, S. P.; Zhang, Y; Chen, W. F. Identification of new cytotoxic T-lymphocyle epitopes from cancer testis antigen HCA587. Biochem. Biophys. Res. Commun. 372(2):331-335; 2008.
7. + T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin. Exp. Immunol. 140(2):310-319; 2005.
8. Godelaine, I).; Carrasco, J.; Brasseur, F.; Neyns, B.; Thielemans, K.; Boon, T.; Van Pel, A. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol. Immunother. 56(6):753-759; 2007.
9. Ma, W.; Gcrmeau, C; Vigneron, N.; Maemoudt, A. S.; Morel, S.; Boon, T.; Coulic, P. G.; Van Den Eynde, B. J. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int. J. Cancer 109(5):698-702; 2004.
10. Ma, W.; Vigneron, N.; Chapiro, J.; Stroobanl, V; Germeau, C; Boon, T.; Coulie, P. G.; Van Den Eynde, B. J. A MAGE-C2 antigenic peptide processed by the immunoprotcasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int. J. Cancer 129(10):2427-2434;2011.
11. Carrasco, J.; Van Pel, A.; Neyns, B.; Lethe, B.; Brasseur, R; Renkvist, N.; Van Der Bruggen, P.; Van Baren, N.; Paulus, R.; Thielemans, K.; Boon, T; Godelaine, D. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 18(5):3585-3593;2008.
12. Germeau, C; Ma, W.; Schiavetti, F; Lurquin, C; Henry, E.; Vigneron, N.; Brasseur, F; Lethe, B.; De Plaen, E.; Velu, T; Boon, T; Coulie, P. G. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. 201(2):241-248; 2005.
13. Lurquin, C; Lethe, B.; De Plaen, E.; Corbiere, V; Theate, 1.; Van Baren, N.; Coulie, P. G.; Boon, T. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 20l (2):249-257; 2005.
14. Chen, J. J.; Zhang, L. J.; Wen, W. G.; Hao, J. Q.; Zeng, P. M.; Qian, X. P.; Zhang, Y; Yin, Y H. Induction of HCA587-specific antitumor immunity with HCA5K7 protein formulated with CpG and ISCOM in mice. PLoS One 7(10):e47219;2012.
15. Kentcr, G. G.; Welters, M. J.; Valentijn, A. R.; Lowik, M. J.; Berends-Vander Meer, D. M.; Vloon, A. P.; Drijfhout, J. W.; Wafeltnan, A. R.; Ooslendorp, J.; Fleurcn, G. J.; Offlinga, R.; Van Der Burg, S. H.; Melief, C. J. Phase I imniunotherapeulic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in endstage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14(1):169-177; 2008.
16. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14(1):178-187; 2008.
17. Spcetjens, F. M; Kuppen, P. J.; Welters, M. J.; Essahsah, R; Voct Van Den Brink, A. M.; Lantrua, M. G.; Valentijn, A. R.; Oostendorp, J.; Fathers, L. M.; Nijman, H. W.; Drijfhout, J. W.; Van De Velde, C. J.; Melief, C. J.; Van Dcr Burg, S. H. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15(3):1086-1095;2009.
18. Khazaie, K.; Boncrtz, A.; Beckhove, P. Current developments with peptide-based human tumor vaccines. Curr. Opin. Oncol. 21(6):524-530; 2009.
19. Melief, C. J.; Van Der Burg, S. H. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8(5):351-360; 2008.
20. Klinman, D. M. Immunotherapcutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4(4):249-258; 2004.
21. Hemmi, H.; Takcuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; Akira, S. A Toll-like receptor recognizes bacterial DNA. Nature. 408(6813):740-745; 2000.
22. Stewart, T. J.; Drane, D.; Malliaros, J.; Elmer, H.; Malcolm, K. M.; Cox, J. C; Edwards, S. J.; Frazer, I. H.; Fernando, G. J. ISCOMATRIX adjuvant: An adjuvant suitable for use in anticancer vaccines. Vaccine 22:3788-3743;2004.
23. Pearse, M. J.; Dranc, D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 57(3):465-474; 2005.
24. + T cells and intratumoral lympholactin transgene expression. Cancer Res. 62(7):2043-2051;2002.
25. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207(3):637-650; 2010.
26. Curicl, T J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mollram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9):942-949; 2004.
27. + T-cell-depcndenl immune defense of B16 melanoma. Cancer Res. 61(24):8643-8646;2001.
28. + T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. I 63(10):5211-5218;1999.
29. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4):295-307; 2006.